These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


908 related items for PubMed ID: 9220222

  • 1. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR, Ory H.
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [Abstract] [Full Text] [Related]

  • 2. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C.
    Lancet; 1995 Dec 16; 346(8990):1589-93. PubMed ID: 7500750
    [Abstract] [Full Text] [Related]

  • 3. Modern oral contraceptives and cardiovascular disease.
    Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J, Mills A.
    Am J Obstet Gynecol; 1997 Sep 16; 177(3):707-15. PubMed ID: 9322646
    [Abstract] [Full Text] [Related]

  • 4. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR.
    Lancet; 1997 Jan 11; 349(9045):83-8. PubMed ID: 8996419
    [Abstract] [Full Text] [Related]

  • 5. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R.
    Contraception; 1997 Sep 11; 56(3):129-40. PubMed ID: 9347202
    [Abstract] [Full Text] [Related]

  • 6. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G, Kohlmeier L, Brenner H.
    Eur J Clin Nutr; 1998 Oct 11; 52(10):711-5. PubMed ID: 9805216
    [Abstract] [Full Text] [Related]

  • 7. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O.
    Am J Obstet Gynecol; 1999 Jun 11; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [Abstract] [Full Text] [Related]

  • 8. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, Stevenson JC.
    Am J Obstet Gynecol; 1993 Nov 11; 169(5):1183-9. PubMed ID: 8238183
    [Abstract] [Full Text] [Related]

  • 9. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP.
    Lancet; 1995 Dec 16; 346(8990):1593-6. PubMed ID: 7500751
    [Abstract] [Full Text] [Related]

  • 10. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD, Lawrenson RA.
    Am J Obstet Gynecol; 1998 Sep 16; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [Abstract] [Full Text] [Related]

  • 11. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
    Contracept Rep; 1996 Apr 16; 7(1):3-6. PubMed ID: 12320047
    [Abstract] [Full Text] [Related]

  • 12. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA, Bonnar J.
    Br J Obstet Gynaecol; 1996 Mar 16; 103(3):261-7. PubMed ID: 8630312
    [Abstract] [Full Text] [Related]

  • 13. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS, Kaye JA, Russmann S, Jick H.
    Contraception; 2006 Jun 16; 73(6):566-70. PubMed ID: 16730485
    [Abstract] [Full Text] [Related]

  • 14. Oral contraceptives and venous thromboembolism: should epidemiologic associations drive clinical decision making?
    Westhoff CL.
    Contraception; 1996 Jul 16; 54(1):1-3. PubMed ID: 8804800
    [Abstract] [Full Text] [Related]

  • 15. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B.
    Ann Pharmacother; 1995 Jul 16; 29(7-8):736-42. PubMed ID: 8520092
    [Abstract] [Full Text] [Related]

  • 16. Myocardial infarction and stroke in young women: what is the impact of oral contraceptives?
    Lewis MA.
    Am J Obstet Gynecol; 1998 Sep 16; 179(3 Pt 2):S68-77. PubMed ID: 9753313
    [Abstract] [Full Text] [Related]

  • 17. Epidemiology of oral contraceptives and cardiovascular disease.
    Chasan-Taber L, Stampfer MJ.
    Ann Intern Med; 1998 Mar 15; 128(6):467-77. PubMed ID: 9499331
    [Abstract] [Full Text] [Related]

  • 18. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1995 Dec 16; 346(8990):1582-8. PubMed ID: 7500749
    [Abstract] [Full Text] [Related]

  • 19. The effects on hemostasis of oral contraceptives containing desogestrel.
    Stubblefield PG.
    Am J Obstet Gynecol; 1993 Mar 16; 168(3 Pt 2):1047-52. PubMed ID: 8447359
    [Abstract] [Full Text] [Related]

  • 20. Progestogens in cardiovascular diseases: an introduction to the epidemiologic data.
    Mann JI.
    Am J Obstet Gynecol; 1982 Mar 15; 142(6 Pt 2):752-7. PubMed ID: 7065056
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 46.